Does the media favor GERN or WHWK?

In the previous week, Geron and Geron both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.42 beat Geron's score of 1.01 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Whitehawk Therapeutics N/A -53.89% -49.97%

Is CADL or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -76.98% -48.50% Whitehawk Therapeutics N/A -53.89% -49.97%

Does the media favor VSTM or WHWK?

In the previous week, Verastem had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 3 mentions for Verastem and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.42 beat Verastem's score of 0.30 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLDB or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% Whitehawk Therapeutics N/A -53.89% -49.97%

Does the media refer more to SLDB or WHWK?

In the previous week, Solid Biosciences had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 3 mentions for Solid Biosciences and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.42 beat Solid Biosciences' score of 0.76 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Whitehawk Therapeutics (WHWK) Competitors

$3.02 -0.36 (-10.65%)

Closing price 04:00 PM Eastern

Extended Trading

$3.02 0.00 (0.00%)

As of 07:37 PM Eastern

Compare

WHWK vs. GERN, ANNX, CADL, VSTM, and SLDB

Should you buy Whitehawk Therapeutics stock or one of its competitors? Whitehawk Therapeutics's main competitors and comparable companies include Geron (GERN), Annexon (ANNX), Candel Therapeutics (CADL), Verastem (VSTM), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Whitehawk Therapeutics compare to Geron?

Geron (NASDAQ:GERN) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Whitehawk Therapeutics has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.26	-$83.50M	-$0.11	N/A
Whitehawk Therapeutics	$7.14M	26.99	-$20.60M	-$1.12	N/A

Whitehawk Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Geron presently has a consensus target price of $4.00, indicating a potential upside of 227.87%. Whitehawk Therapeutics has a consensus target price of $8.33, indicating a potential upside of 146.55%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Whitehawk Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Geron has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

73.7% of Geron shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Geron and Geron both had 2 articles in the media. Whitehawk Therapeutics' average media sentiment score of 1.42 beat Geron's score of 1.01 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Whitehawk Therapeutics beats Geron on 9 of the 15 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Annexon?

Annexon (NASDAQ:ANNX) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Annexon has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than Annexon. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 1 mentions for Annexon. Annexon's average media sentiment score of 1.82 beat Whitehawk Therapeutics' score of 1.42 indicating that Annexon is being referred to more favorably in the media.

Company	Overall Sentiment
Annexon	Very Positive
Whitehawk Therapeutics	Positive

52.1% of Whitehawk Therapeutics shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Whitehawk Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Whitehawk Therapeutics	$7.14M	26.99	-$20.60M	-$1.12	N/A

Whitehawk Therapeutics' return on equity of -53.89% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Annexon currently has a consensus target price of $15.29, suggesting a potential upside of 286.00%. Whitehawk Therapeutics has a consensus target price of $8.33, suggesting a potential upside of 146.55%. Given Annexon's higher possible upside, analysts clearly believe Annexon is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Whitehawk Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Whitehawk Therapeutics beats Annexon on 11 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Whitehawk Therapeutics has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Whitehawk Therapeutics	$7.14M	26.99	-$20.60M	-$1.12	N/A

Whitehawk Therapeutics' return on equity of -53.89% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Candel Therapeutics has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 1.79 beat Whitehawk Therapeutics' score of 1.42 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Candel Therapeutics	Very Positive
Whitehawk Therapeutics	Positive

Candel Therapeutics presently has a consensus price target of $20.14, indicating a potential upside of 105.96%. Whitehawk Therapeutics has a consensus price target of $8.33, indicating a potential upside of 146.55%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Whitehawk Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Whitehawk Therapeutics beats Candel Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Verastem?

Verastem (NASDAQ:VSTM) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

In the previous week, Verastem had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 3 mentions for Verastem and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.42 beat Verastem's score of 0.30 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verastem presently has a consensus target price of $13.83, suggesting a potential upside of 67.68%. Whitehawk Therapeutics has a consensus target price of $8.33, suggesting a potential upside of 146.55%. Given Whitehawk Therapeutics' higher probable upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Whitehawk Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Whitehawk Therapeutics has lower revenue, but higher earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	24.17	-$209.47M	-$2.66	N/A
Whitehawk Therapeutics	$7.14M	26.99	-$20.60M	-$1.12	N/A

Whitehawk Therapeutics has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Whitehawk Therapeutics' return on equity of -53.89% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Verastem has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

88.4% of Verastem shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 1.9% of Verastem shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Whitehawk Therapeutics beats Verastem on 11 of the 15 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Whitehawk Therapeutics' return on equity of -53.89% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Whitehawk Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Whitehawk Therapeutics	$7.14M	26.99	-$20.60M	-$1.12	N/A

Solid Biosciences has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

In the previous week, Solid Biosciences had 1 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 3 mentions for Solid Biosciences and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.42 beat Solid Biosciences' score of 0.76 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences presently has a consensus price target of $18.69, suggesting a potential upside of 178.57%. Whitehawk Therapeutics has a consensus price target of $8.33, suggesting a potential upside of 146.55%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Solid Biosciences is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Whitehawk Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Whitehawk Therapeutics beats Solid Biosciences on 8 of the 14 factors compared between the two stocks.

Get Whitehawk Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WHWK vs. The Competition

Export

Metric	Whitehawk Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$192.69M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	8.33	177.90	18.12
Price / Sales	24.11	1,149.10	561.77	81.05
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.04	16.95	10.71	6.03
Net Income	-$20.60M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-16.34%	-4.83%	-3.18%	-3.04%
1 Month Performance	-26.52%	-12.20%	-6.61%	-5.16%
1 Year Performance	48.04%	8.87%	3.69%	-2.48%

Whitehawk Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WHWK Whitehawk Therapeutics	2.6483 of 5 stars	$3.02 -10.7%	$8.33 +175.9%	+67.3%	$192.69M	$7.14M	N/A	23	Positive News
GERN Geron	2.4727 of 5 stars	$1.22 +1.7%	$4.00 +227.9%	-6.9%	$770.97M	$183.88M	N/A	258	News Coverage Positive News
ANNX Annexon	3.8252 of 5 stars	$4.00 -0.2%	$15.29 +282.1%	+27.7%	$760.21M	N/A	N/A	92	Positive News
CADL Candel Therapeutics	2.8875 of 5 stars	$9.66 -1.6%	$20.14 +108.5%	+58.0%	$751.41M	N/A	N/A	55	Positive News
VSTM Verastem	3.4253 of 5 stars	$8.11 -1.9%	$13.83 +70.6%	-3.7%	$748.51M	$30.91M	N/A	102

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WHWK) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. GERN, ANNX, CADL, VSTM, and SLDB

How does Whitehawk Therapeutics compare to Geron?

Summary

How does Whitehawk Therapeutics compare to Annexon?

Summary

How does Whitehawk Therapeutics compare to Candel Therapeutics?

Summary

How does Whitehawk Therapeutics compare to Verastem?

Summary

How does Whitehawk Therapeutics compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. GERN, ANNX, CADL, VSTM, and SLDB

How does Whitehawk Therapeutics compare to Geron?

Which has better valuation & earnings, GERN or WHWK?

Is GERN or WHWK more profitable?

Do analysts recommend GERN or WHWK?

Which has more risk & volatility, GERN or WHWK?

Do insiders and institutionals believe in GERN or WHWK?

Does the media favor GERN or WHWK?

Summary

How does Whitehawk Therapeutics compare to Annexon?

Which has more risk & volatility, ANNX or WHWK?

Does the media favor ANNX or WHWK?

Do institutionals & insiders hold more shares of ANNX or WHWK?

Which has better valuation and earnings, ANNX or WHWK?

Is ANNX or WHWK more profitable?

Do analysts rate ANNX or WHWK?

Summary

How does Whitehawk Therapeutics compare to Candel Therapeutics?

Do institutionals & insiders believe in CADL or WHWK?

Which has preferable valuation & earnings, CADL or WHWK?

Is CADL or WHWK more profitable?

Which has more volatility and risk, CADL or WHWK?

Does the media refer more to CADL or WHWK?

Do analysts recommend CADL or WHWK?

Summary

How does Whitehawk Therapeutics compare to Verastem?

Does the media favor VSTM or WHWK?

Do analysts recommend VSTM or WHWK?

Which has higher earnings and valuation, VSTM or WHWK?

Is VSTM or WHWK more profitable?

Which has more risk & volatility, VSTM or WHWK?

Do institutionals and insiders hold more shares of VSTM or WHWK?

Summary

How does Whitehawk Therapeutics compare to Solid Biosciences?

Is SLDB or WHWK more profitable?

Which has stronger valuation & earnings, SLDB or WHWK?

Which has more risk & volatility, SLDB or WHWK?

Does the media refer more to SLDB or WHWK?

Do analysts rate SLDB or WHWK?

Do institutionals & insiders hold more shares of SLDB or WHWK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools